When Google showed an AI Overview on a US pharmaceutical search, the domain ranking first in the organic results was cited in that AI-written answer 68.8% of the time, according to a study by performance.io and Semrush, an Adobe company, that Semrush announced on November 16, 2026. The citation rate fell with every position down the page, and 83.8% of all AI Overview domain citations in the sample went to domains ranking in the organic top 10.

The same data carries a less comfortable result for drug companies. Pharma brand websites held 9.2% of the No. 1 organic positions in the sample but received only 4.2% of AI Overview citations, the largest proportional gap of any domain type the authors tracked. Reddit, a frequent source in Google's AI answers on shopping queries, accounted for 0.15% of citations.

In Short

A pharma-focused search agency and Semrush tracked about 14,300 US health and drug keywords for four years and found that Google's AI Overviews mostly cite the websites that already rank at the top of the normal results. That matters to drug brands, publishers and health organisations because ranking well still appears to buy a seat inside the AI answer, even as estimated traffic declines. What changes is the yardstick: the authors argue that citations, and how many times a site is cited inside one answer, now sit next to traffic as a measure of search performance, though the study shows association rather than cause.

Who ran the study and how

performance.io led the analysis on Semrush data. Semrush's announcement describes it as a specialist pharma and healthcare agency; the agency's own website says it helps 15 of the world's top 20 pharma and biotech companies stay visible across Google, AI Overviews and large language models. Both companies sell the products the study evaluates - Semrush the tracking data, performance.io the search services - and the white paper is explicit that its closing view rests partly on the agency's experience. On the question of whether the brand case studies prove that investment works, the authors write that they "fall back on our own industry and professional opinion on this conclusion."

The white paper is titled "Rank Still Wins: About Organic Position and AI Overview Citations in Pharma Search" and carries the subtitle "An observational analysis of organic rank and domain-level AI Overview citations in US pharma search, 2022-2026." It is undated. performance.io's page for the paper carries an October 15, 2026 publication date, and Semrush says the research was previewed at its Spotlight 2026 conference before the November 16 announcement. Semrush's announcement lists the summary under a slightly different title, "Rank Still Wins: How Organic Position Drives AI Overview Citations in Pharma Search." Matt Lowe, chief executive of performance.io, and David Power, Semrush's global head of partnerships, are named in that announcement.

According to the white paper, the analysis was assembled in six steps:

  1. Market and device. The authors chose the United States, citing its lighter rules on direct-to-consumer drug marketing, its role as the first market where Google tests and launches updates, and the availability of historical results data. Only desktop results were tracked.
  2. Therapeutic areas. Five areas were selected to vary in seasonality, disease origin, treatment modality and patient versus professional search behaviour: Alzheimer's disease, type 2 diabetes, non-small-cell lung cancer, plaque psoriasis and respiratory syncytial virus.
  3. Keyword lists. Each area received a branded and a non-branded list, ten lists in all, holding 14,334 unique keywords. Twenty-four keywords sat in both lists of their area, giving 14,358 keyword-list entries. Brands were picked at different lifecycle stages: early launch, growth, established and patent cliff.
  4. Data pull. The lists were run through Semrush Position Tracking for 48 months, August 2022 to July 2026. That produced 689,184 requested keyword-month slots (14,358 x 48). Semrush returned results-page data for 340,660 of them, 49%, which the paper calls snapshots and which form the whole analysis base.
  5. Domain classification. Every domain in the organic results was sorted into nine buckets: PubMed/NLM, .gov, .edu, Major Health Publisher, Disease Association, Pharma Brand, pharmacy and savings sites (labelled DSE Pharmacy), YouTube and "Other." The authors say they spot-checked the "Other" bucket so that major sources were not hidden there.
  6. Matching citations. A citation is counted at domain level. In the paper's glossary: "We match citations at domain level, so a citation means the website's domain appears in the feature's source list. We do not measure clicks."
Item Detail (according to the white paper)
Lead analyst performance.io, on Semrush data
Data tool Semrush Position Tracking
Market and device United States, desktop only
Period August 2022 to July 2026 (48 months)
AI Overview window First seen in the September 2024 snapshot; analysis to July 2026
Unique keywords 14,334 in ten lists (14,358 keyword-list entries)
Requested keyword-month slots 689,184
Slots with results data (snapshots) 340,660 (49%)
AI Overview domain appearances 325,549
Individual links inside those AI Overviews 493,945
Matching level Domain, not URL
Traffic Semrush modelled estimates, not measured clicks
Study type Observational; associations, not causes

One number in the announcement does not match the paper. Semrush's announcement refers to more than 689,100 keyword snapshots across 48 months. In the white paper, 689,184 is the number of slots requested; the snapshots analysed number 340,660, about half that figure. The paper is plain about the limits of its traffic data: "Traffic figures are Semrush's modelled estimates, not measured clicks, and findings apply to this sample of US pharma queries."

Three home-made measures

The authors built three metrics from the Semrush export, each describing the SERP, or search engine results page, in a different way. Their definitions, quoted from the methods section and glossary, set out exactly what each one counts.

Metric Definition (verbatim from the white paper) Weighting
Organic Displacement Score "Organic Displacement Score measures how many distinct SERP feature types render above organic result #1 for a given keyword-snapshot." Each feature type counts as 1, whatever its size; zero when organic #1 renders first
SERP Crowding Score "SERP Crowding Score measures total page noise" Pixel height relative to one organic result: AI Overview 3.44x, People Also Ask 2.07x, Image Pack 3.03x, all others 1.0x; position does not matter
Influence Score "Whether a website is cited by any of the Big 3 (AI Overview, People Also Ask or Knowledge Panel) in a given search, and whether that goes with higher modelled traffic. It is a yes-or-no measure, not a count" Compared on era-controlled indexed traffic

A crowded page before the AI arrived

The first finding concerns timing. Organic links on these pharma results pages were competing with other features long before Google added AI summaries. By August 2024, according to the study, total page crowding had reached roughly 2.5 units on the Crowding Score, about half of the level of around 5 it would reach by 2026. Over the same years, the Displacement Score - features sitting above the first organic link - stayed near zero.

That changed when AI Overviews appeared. Google released the feature in May 2024, initially under the Search Generative Experience name, and the study first records it in pharma results in the September 2024 snapshot, after a mid-August 2024 breakthrough in the vertical. "The results are clear: AIOs land ahead of everything else on the SERP 98.63% of the time," the authors write. In the remaining 1.37% of cases, the first organic link sat above the AI Overview, and that share has been growing since May 2025, reaching 2.4% by July 2026.

No other feature behaved that way. Local Pack beat everything else to the top slot 48.6% of the time when it appeared, Image Pack and Top Stories did so at rates in the high teens, and People Also Ask only 4.5% of the time. AI Overviews also thinned out the features around them. People Also Ask appeared on 89.4% of results pages without an AI Overview and 70.2% with one; Knowledge Panels fell from 11.3% to 6.0%; Featured Snippets from 54.7% to 6.9%. The authors dropped Featured Snippets from the rest of the analysis because their data could not show where snippets landed or which links they were drawn from.

Traffic tells a different story from rankings. The median modelled traffic of the No. 1 URL rose through the crowding years and peaked in August 2024 at 9,390, the month before AI Overviews appear in the data. It has fallen since, with sharp swings, but has not dropped far below its August 2022 starting level. The authors concede their design cannot separate the AI effect from the older decline: "our study design can't separate this out from the already decreasing trend." They cite SparkToro figures for broader US Google search, in which zero-click searches rose from 49% in 2019 to 60% in 2024 and 68% in early 2026, and note that those figures come from different panels.

Rank and the citation

The central result is the link between organic position and AI Overview citation, measured when an AI Overview was present on the page.

Organic position AI Overview citation rate (domain level)
1 69% (pooled 68.8%)
2 57%
3 44%
4 34%
5 26%
6 21%
7 19%
8 16%
9 15%
10 13%

The No. 1 rate held up over time. Across the 23 months from September 2024 to July 2026, the monthly rate moved between roughly 55% and 77%, with a mean of the monthly rates of 68.7%. In this dataset, 83.8% of AI Overview domain citations came from domains in the organic top 10.

The pattern repeats in other features, with two exceptions. In People Also Ask, the second-ranked link was cited more often (43.3%) than the first (36.7%), matched by domain; the authors speculate that second-ranked pages may target narrower questions. In video carousels, citation rates rose further down the organic list. Being cited in one feature did little for the chances of being cited in another: the phi coefficient between AI Overview and People Also Ask citations was 0.10, and between People Also Ask and Knowledge Panel it was negative at -0.15. The strongest pairings were Knowledge Panel with Local Pack (0.29), Knowledge Panel with video carousel (0.26) and Local Pack with video carousel (0.24).

How the pharma numbers compare with broader studies

The authors set their figures against wider web studies and warn that methods differ. Their own match is at domain level, which is more permissive than URL matching, and covers a fixed set of US pharma queries. The comparison figures below are those cited in the white paper, labelled by publisher.

Publisher (as cited in the white paper) Measure Figure
performance.io and Semrush (pharma, domain level) No. 1 organic result cited in AI Overview 68.8%
performance.io and Semrush (pharma, domain level) Share of AI Overview citations from organic top 10 83.8%
Semrush (July 22, 2025; data collected September 2024) No. 1 result cited in AI Overview 46% desktop, 34% mobile
Ahrefs (July 21, 2025) Top-10 share of citations (cited URLs, first three per AI Overview) 76.1%
Ahrefs (March 2, 2026) Top-10 share of citations 37.1% in the white paper; Ahrefs' headline says 38%
BrightEdge (2025) Top-10 share of citations 17%
BrightEdge (2025, 2026) Share of citations from pages ranking organically 32% in May 2024, 54% in September 2025
Semrush (2025) Overlap with top-10 results 20% to 26%

The spread across that table is wide, and PPC Land has reported the moving target before. Cyrus Shepard's review of 54 studies, covered in May 2026, scored search rank 9.4 out of 10 as an AI citation factor while carrying the Ahrefs figure that only 38% of AI Overview citations came from the top 10. Ahrefs data from July 2025 found that only 8.64% of AI Overviews appeared outside the top position across 10 million results pages in 10 countries, consistent with the 98.63% top placement the pharma study records.

Who gets cited, and how often

The domain-type breakdown is where the study's headline for marketers sits. The white paper says pharma domains "appear to be at a disadvantage in this citation economy relative to the other domains in the data set."

Domain type AI Overview citation share minus organic #1 share Change in #1 share, 2022 to 2026 Mean Displacement Score when #1 Citation instances per AI Overview appearance
Pharma Brand -5.1 pp (9.2% of #1 spots, 4.2% of citations) +4% 0.28 1.86
.gov -2.3 pp -33% 0.35 1.73
Disease Association -1.7 pp +60% 0.44 1.52
Major Health Publisher -1.0 pp -3% 0.36 1.47
DSE Pharmacy -0.0 pp +53% 0.32 1.60
PubMed +0.9 pp +146% 0.48 1.55
YouTube +1.3 pp +13% 0.40 1.38
.edu +1.7 pp +146% 0.40 1.39
Other +6.2 pp -45% 0.28 1.38

Pharma brand sites, in other words, earned citations at less than half the rate their No. 1 positions would imply (4.2 divided by 9.2 is 46%, a PPC Land calculation). "This is the largest proportional drop of any domain type tracked," the paper states. Government sites were not favoured either: .gov domains held a larger share of No. 1 rankings than of AI Overview citations. The domains that over-indexed were the reference authorities, PubMed and .edu, and above all the long-tail "Other" bucket, which gained 6.2 points.

The authors offer no firm explanation, only a working idea built on YMYL, Google's label for topics that can affect health, finances or safety. "We currently don't have an explanation for this, but our working hypothesis is that organic ranking weighs YMYL regulations more heavily than AIO source selection does as AIOs synthesise a response from multiple sources to answer a broader question," they write. The paper also cites Google Search Central's guidance on the E-E-A-T framework of experience, expertise, authoritativeness and trustworthiness, in which Google says it gives "even more weight to content that aligns with strong E-E-A-T" on such topics.

Over four years, the holders of the top organic slot shifted. PubMed and .edu each grew their share of No. 1 positions by 146% between 2022 and 2026, disease associations by 60% and pharmacy and savings sites by 53%. The long-tail "Other" domains lost 45% and .gov sites 33%. The low Displacement Score for pharma brands, the authors note, is not a sign that brands defend their positions better; their keywords trigger AI Overviews less often in the first place.

Citation depth

A second dimension partly reverses the picture. A single AI Overview often links to the same domain several times, for different sections of an answer. Of the 325,549 domain appearances in the data, 41.8% had two or more links, and the overall average was 1.52 links per appearance (493,945 links divided by 325,549 appearances gives 1.517, a PPC Land calculation that matches the paper's figure).

Once inside an answer, pharma brands were linked most often: 1.86 times per appearance, ahead of .gov (1.73), pharmacy and savings sites (1.60), PubMed (1.55) and disease associations (1.52). Rank mattered here too. Domains in the organic top three averaged 1.71 links per appearance, positions four to ten averaged 1.33, and domains outside the top 10 averaged 1.29. The domain ranking first averaged 1.94.

Reddit, YouTube and the YMYL question

The Reddit figure is the one most likely to travel. Across the full period, Reddit took 0.15% of AI Overview citations in the pharma sample and YouTube 1.76%. Neither made the ten most cited domains: YouTube ranked 12th and Reddit 80th. For comparison the paper cites an all-industry study by Profound, published on June 5, 2025, which put YouTube at 1.9% and Reddit at 2.2% of AI Overview citations, and an Ahrefs 2026 figure of 5.6% of cited URLs for YouTube. The 2.2% is Profound's figure across industries, not a pharma baseline from the study's own data.

Measure (pharma sample, according to the white paper) YouTube Reddit
Share of AI Overview citations, full period 1.76% 0.15%
Rank among most cited domains 12th 80th
Share of AI Overview blocks citing the platform, July 2026 15.3% 1.6%
Share of organic top-3 results held, end of period 1.5% 1.4%
Share of all organic top-10 rows 1.06% 0.30%
Share of own appearances at organic position 1 6.6% 4.4%
Share of own appearances at organic position 10 17.2% 15.6%

The time series complicates the full-period averages. YouTube's presence in pharma AI Overviews "rose sharply in 2026," according to the paper, reaching 15.3% of AI Overview blocks by July 2026, while its share of organic top-three results stayed near 1.5%. Reddit's line, close to zero through 2025, jumped early in 2026 and ended July at 1.6% of AI Overview blocks. Both platforms appear mostly at the bottom of the first page when they rank at all.

The authors tie the low forum presence to how Google treats health topics, and cite a small qualitative study in The Permanente Journal (Geracitano, Mendis and Khairat, 2026) in which clinicians relied on peer-reviewed literature while patients leaned on platforms such as Reddit and TikTok. They are careful about the leap: "Since patient search makes up a far greater share of pharma search volume than clinician search, the low citation share for these platforms is more directly explained by how Google surfaces sources in the YMYL space."

Google itself signalled such a split early. Days after the US launch in May 2024, when AI Overviews were suggesting glue on pizza and drinking urine to pass kidney stones, the company said it would limit reliance on forum content and tighten safeguards for health queries. The pharma figures contrast sharply with retail. In Semrush's holiday study in November 2026, Reddit was cited in 35.2% of tracked AI Overview prompts, rising to 53.2% for Christmas gift prompts. Forums are not out of the health conversation altogether: in June 2026, r/biohackers moderators restricted new peptide and HRT posts after companies used the subreddit to shape AI answers.

Traffic: the "Big 3" comparison

The Influence Score tests whether a citation in AI Overviews, People Also Ask or Knowledge Panel comes with more traffic. It uses keyword-indexed traffic: each keyword's modelled traffic divided by its own average from September 2024 to July 2026 and multiplied by 100, restricted to keywords with at least 12 months of data in that window.

Among No. 1 ranking domains, median indexed traffic was 86.4 when the domain was cited by any of the three features and 82.4 when it was not, about 5% higher, across 95,591 and 70,414 keyword-month observations. The difference came mostly from People Also Ask and Knowledge Panel citations, at 96.1, about 17% above uncited. AI Overview citation alone came in at 82.9, about 1% above. The authors suggest that may reflect the AI Overview's position on top of the page rather than a lower value for the citation itself, and say the pattern held across cuts by search volume and keyword difficulty, data they did not publish.

That is a modest edge on modelled numbers, and it sits against a wider decline in click-through. Ahrefs data reported in February 2026 tied AI Overviews to a 58% lower click-through rate for top-ranking pages, and SparkToro research published on November 10, 2026 found visits to the top one million websites down 12.2% between the first quarter of 2022 and the third quarter of 2026.

Patients and professionals

The keyword lists separated queries written the way healthcare professionals search from those written the way patients search. Organic share - the part of the page held by ordinary results - fell more for patient-facing queries.

Query length HCP queries, decline in organic share 2022 to 2026 Patient queries, decline in organic share 2022 to 2026
1-2 words 17.9% 22.2%
3-4 words 18.2% 22.2%
5-6 words 19.6% 22.9%
7+ words 17.5% 22.4%

Query length made little difference, which the authors read as consistent with different search behaviour between the two audiences.

Five brands, anonymised

The paper follows five unnamed brands, labelled by therapy: a type 2 diabetes (T2D) brand near the end of its patent, a non-small-cell lung cancer (NSCLC) brand facing new competitors, a mature psoriasis brand, a vaccine brand that launched during the study period, and the oldest of the five, a neurology brand.

Four of the five held the top organic slot for their own drug name. The T2D, NSCLC and psoriasis brands stayed at No. 1 throughout, except for a single-month lapse for the psoriasis brand. The vaccine brand reached No. 1 several months after launch and held it consistently only after a year. The neurology brand did not hold No. 1 at all.

Where the brands ranked first for their own brand queries and an AI Overview appeared, the AI Overview cited the brand's own domain 78% of the time, or 83.4% including sister sites such as HCP or savings sites, above the 68.8% across all keywords. AI Overviews on those brand No. 1 snapshots became far more common over the period: from 9% (35 of 414 keyword-month observations) in September 2024 to 89% (651 of 729) in July 2026. The paper calls the early base thin; 35 of 414 works out at 8.5%, a PPC Land calculation, slightly below the 9% stated.

Brand Buying-signal keywords owned, 2022 Buying-signal keywords owned, 2026 Links per AI Overview when #1 and cited (incl. sister sites) Median traffic, Big 3 cited vs not (May-Jul 2026)
T2D Brand 48.7% 39.1% 2.51 +174.3%
NSCLC Brand 61.1% 43.5% 2.43 +61.9%
Psoriasis Brand 83.2% 86.8% 2.60 -74.3%
Vaccine Brand not reported not reported 2.29 +6.4%
Neurology Brand not reported not reported not reported not reported

Buying-signal queries cover handling, dosing, initiation, switching and discontinuation; the authors could pull representative results for only three brands. Counting own-domain links only, cited brand pages averaged 2.2 to 2.4 links per AI Overview, above the 1.94 for any No. 1 domain. Modelled traffic still fell for brands that held No. 1 when AI Overviews arrived, and only the T2D brand restored its traffic to a comparable level. The traffic comparison in the last column uses May to July 2026 and small keyword counts, and the authors describe it as "illustrative rather than conclusive."

What the study does not establish

The study measures where domains appear, not what searchers do. It has no click, impression or click-through data, uses Semrush's modelled traffic, covers desktop only, matches citations by domain rather than page, and rests on the 49% of requested slots that returned data. The five therapy areas and anonymised brands cannot be checked against named sites, and the case-study comparisons rely on short windows. The authors call the work exploratory and preliminary, and say a look at large language model chatbots would be a natural next step; they cite Datos and SparkToro data putting LLMs at 1.83% of US desktop activity against 10.5% for traditional search.

Why this matters for search marketers

The volume at stake is large. In March 2026, Google said it receives more than one billion health questions a day. Health publishers have been losing ground for some time, and WebMD and Healthline visibility fell further after the December 2025 core update. In France, Glenn Gabe's November 2026 analysis found that two of five sites hit after the AI Overviews launch were YMYL sites, with one falling from about 80 to about 25 clicks a day.

For drug marketers the stakes run through both organic and paid channels. The Video Advertising Bureau's November 2026 guide put pharma TV spending at $6.9bn in 2025, down 4%, while digital pharma spending rose 21% to $18.7bn on an eMarketer forecast. Google opened a small US test of healthcare ads in AI Mode in June 2026. And AI Overviews keep spreading on the commercial side: Semrush found them on 88% of tracked commercial keywords in August 2026, up from 45.75% a year earlier.

Brand searches are also changing after the study's July 2026 cut-off. Since early November 2026, Google has been showing AI Overviews for many brand queries in the right-hand column, the space Knowledge Panels have used, a change Google has not announced. The study's finding that AI Overviews sit above everything else 98.63% of the time predates that layout, so the own-brand results may not hold in the same form.

There is also the commercial setting of the research itself. Adobe agreed to buy Semrush for $1.9bn in November 2025, and Semrush now sells AI visibility tracking alongside traditional rank data. The white paper deliberately uses "SEO" for everything, including what others call GEO and AEO - a choice that fits the industry argument over new acronyms and the paper's central claim. In its words, the analysis "confirms what we have long suspected anecdotally: strong traditional SEO strategy still holds weight in the age of AI search." The data supports a narrower version of that: in this sample, ranking first went with being cited, and being cited went with a small traffic edge, while the traffic itself kept falling.

Key facts

  • Study title: "Rank Still Wins: About Organic Position and AI Overview Citations in Pharma Search" (Semrush's announcement lists the summary as "Rank Still Wins: How Organic Position Drives AI Overview Citations in Pharma Search")
  • Subtitle: "An observational analysis of organic rank and domain-level AI Overview citations in US pharma search, 2022-2026"
  • Authors: performance.io (lead analysis), in partnership with Semrush, an Adobe company; no individual authors named
  • Announcement: Semrush news release, November 16, 2026: "Semrush and performance.io Research Reveals How Pharma Brands Appear in Google AI Overviews" - https://www.semrush.com/news/477927-semrush-and-performanceio-research-reveals-how-pharma-brands-appear-in-google-ai-overviews/
  • Paper page: https://www.performance-io.com/rank-still-wins-ai-overviews-pharma/ (dated October 15, 2026, last modified November 13, 2026; download behind a form)
  • People named in the announcement: Matt Lowe, CEO, performance.io; David Power, Global Head of Partnerships, Semrush
  • Data source: Semrush Position Tracking, US desktop
  • Period: August 2022 to July 2026; AI Overviews first in the September 2024 snapshot
  • Sample: 14,334 unique keywords, 14,358 keyword-list entries, 689,184 requested slots, 340,660 snapshots (49%)
  • Therapeutic areas: Alzheimer's disease, type 2 diabetes, non-small-cell lung cancer, plaque psoriasis, respiratory syncytial virus
  • Headline figures: No. 1 domain cited in 68.8% of AI Overviews; 83.8% of citations from top 10; AI Overview above all other features 98.63% of the time; pharma brands 9.2% of #1 spots vs 4.2% of citations; Reddit 0.15% and YouTube 1.76% of citations; pharma brands 1.86 links per appearance; own-brand AI Overview citation 78% (83.4% with sister sites)
  • Metrics introduced: Organic Displacement Score, SERP Crowding Score, Influence Score ("Big 3": AI Overview, People Also Ask, Knowledge Panel)

Timeline

Summary

Who: performance.io, an SEO and GEO agency working with pharmaceutical companies, which led the analysis, and Semrush, an Adobe company, which supplied the Position Tracking data and announced the research.

What: An observational study of 14,334 US pharma keywords and 340,660 monthly results-page snapshots. When an AI Overview appeared, the No. 1 organic domain was cited 68.8% of the time and 83.8% of citations came from the top 10. Pharma brand sites held 9.2% of No. 1 positions but 4.2% of citations, though they were linked more times per answer (1.86) than any other domain type. Reddit took 0.15% of citations and YouTube 1.76%, with YouTube's presence rising sharply in 2026.

When: Semrush announced the research on November 16, 2026. The data runs from August 2022 to July 2026, with AI Overviews first recorded in September 2024.

Where: Google search results in the United States, desktop only, across Alzheimer's disease, type 2 diabetes, non-small-cell lung cancer, plaque psoriasis and respiratory syncytial virus.

Why: Drug brands, health publishers and their agencies are trying to work out whether organic ranking still pays as AI Overviews take the top of the page and modelled traffic falls. The study suggests rank remains closely tied to being cited, while showing that citation alone brought only a small traffic difference and that brand sites are under-cited relative to their rankings.